PP
CLSD

Paloma Partners’s Clearside Biomedical CLSD Stock Holding History

Paloma Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-8,387
Closed -$122K – 1999
2019
Q2 		$122K Buy
+8,387
New +$150K ﹤0.01% 1606
2018
Q1 		– Sell
-1,180
Closed -$124K – 1984
2017
Q4 		$124K Buy
+1,180
New +$127K ﹤0.01% 1782

Other funds holding CLSD

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
S
SignatureFD Atlanta, Georgia $7.49B AUM 24.82% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

Paloma Partners's CLSD Position: Q3 2019 in Review

Paloma Partners sold out of Clearside Biomedical (CLSD) in Q3 2019, closing a stake of 8,387 shares — an estimated $122K sold.

Paloma Partners first reported a position in CLSD in Q4 2017 and held it in 2 quarters. The position peaked at $124K in Q4 2017. 34 funds tracked by Wall St. Rank hold CLSD as of Q3 2019.

  • Paloma Partners reported no remaining Clearside Biomedical position as of Q3 2019 after selling out during the quarter.
  • Paloma Partners sold 8,387 Clearside Biomedical shares in Q3 2019, an estimated $122K.
  • Paloma Partners first reported a position in Clearside Biomedical in Q4 2017 and held it in 2 quarters.
  • Paloma Partners's Clearside Biomedical position peaked at $124K in Q4 2017.
  • 34 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2019.

Based on Paloma Partners's 13F filing for Q3 2019, filed 14 Nov 2019.